Heat shock proteins in hematopoietic malignancies

Experimental Cell Research

Volumn 318, Issue 15, 2012, Pages 1946-1958

  Mjahed, Hajare ^a,b   Girodon, François ^a,b,c   Fontenay, Michaela ^d,e,f   Garrido, Carmen ^a,b,c  

^a Chu   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

^d INSTITUT COCHIN   (France)

^e INSERM   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Apoptosis; Cell differentiation; Emerging chemotherapeutic treatments; Heat shock proteins; Hematological malignancies; Myelodysplastic syndromes

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; ALVESPIMYCIN; ANSAMYCIN DERIVATIVE; AT 13387; BIIB 021; CASPASE; CHAPERONE; CNF 2024; CYSTEINE PROTEINASE; DS 2248; GANETESPIB; GELDANAMYCIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HEAT SHOCK PROTEIN 90ALPHA; HEAT SHOCK PROTEIN 90BETA; HISTONE DEACETYLASE INHIBITOR; IPI 493; KW 2478; MPC 3100; PANOBINOSTAT; POLYARGININE; PUH 71; RETASPIMYCIN; SNX 2112; TANESPIMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; CELL FATE; CELL PROLIFERATION; CELL PROTECTION; CELL STRESS; CELL SURVIVAL; CELL TRANSFORMATION; CHROMATIN CONDENSATION; CHRONIC MYELOID LEUKEMIA; ENZYME ACTIVATION; GENE OVEREXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; LARGE CELL LYMPHOMA; MYELODYSPLASTIC SYNDROME; MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN TARGETING;

EID: 84863784534     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.05.012     Document Type: Article

References (170)

1. Garrido C., Brunet M., Didelot C., Zermati Y., Schmitt E., Kroemer G. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 2006, 5:2592-2601.
2. Macario A.J., Conway de Macario E. The pathology of cellular anti-stress mechanisms: a new frontier. Stress 2004, 7:243-249.
3. Parcellier A., Gurbuxani S., Schmitt E., Solary E., Garrido C. Heat shock proteins, cellular chaperones that modulate mitochondrial cell death pathways. Biochem. Biophys. Res. Commun. 2003, 304:505-512.
4. Lanneau D., Brunet M., Frisan E., Solary E., Fontenay M., Garrido C. Heat shock proteins: essential proteins for apoptosis regulation. J. Cell Mol. Med. 2008, 12:743-761.
5. Jego G., Hazoume A., Seigneuric R., Garrido C. Targeting heat shock proteins in cancer. Cancer Lett. 2010.
6. Garrido C., Paul C., Seigneuric R., Kampinga H.H. The small heat shock proteins family: the long forgotten chaperones. Int. J. Biochem. Cell Biol. 2012.
7. Hayes D., Napoli V., Mazurkie A., Stafford W.F., Graceffa P. Phosphorylation dependence of hsp27 multimeric size and molecular chaperone function. J. Biol. Chem. 2009, 284:18801-18807.
8. Theriault J.R., Lambert H., Chavez-Zobel A.T., Charest G., Lavigne P., Landry J. Essential role of the NH2-terminal WD/EPF motif in the phosphorylation-activated protective function of mammalian Hsp27. J. Biol. Chem. 2004, 279:23463-23471.
9. Garrido C. Size matters: of the small HSP27 and its large oligomers. Cell Death Differ. 2002, 9:483-485.
10. Bruey J.M., Paul C., Fromentin A., Hilpert S., Arrigo A.P., Solary E., Garrido C. Differential regulation of HSP27 oligomerization in tumor cells grown in vitro and in vivo. Oncogene 2000, 19:4855-4863.
11. Rogalla T., Ehrnsperger M., Preville X., Kotlyarov A., Lutsch G., Ducasse C., Paul C., Wieske M., Arrigo A.P., Buchner J., Gaestel M. Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/tumor necrosis factor alpha by phosphorylation. J. Biol. Chem. 1999, 274:18947-18956.
12. Kostenko S., Moens U. Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology. Cell. Mol. Life Sci. 2009, 66:3289-3307.
13. Parcellier A., Schmitt E., Brunet M., Hammann A., Solary E., Garrido C. Small heat shock proteins HSP27 and alphaB-crystallin: cytoprotective and oncogenic functions. Antioxid. Redox Signal 2005, 7:404-413.
14. Lambert H., Charette S.J., Bernier A.F., Guimond A., Landry J. HSP27 multimerization mediated by phosphorylation-sensitive intermolecular interactions at the amino terminus. J. Biol. Chem. 1999, 274:9378-9385.
15. Kato K., Hasegawa K., Goto S., Inaguma Y. Dissociation as a result of phosphorylation of an aggregated form of the small stress protein, hsp27. J. Biol. Chem. 1994, 269:11274-11278.
16. Vertii A., Hakim C., Kotlyarov A., Gaestel M. Analysis of properties of small heat shock protein Hsp25 in MAPK-activated protein kinase 2 (MK2)-deficient cells: MK2-dependent insolubilization of Hsp25 oligomers correlates with susceptibility to stress. J. Biol. Chem. 2006, 281:26966-26975.
17. Butt E., Immler D., Meyer H.E., Kotlyarov A., Laass K., Gaestel M. Heat shock protein 27 is a substrate of cGMP-dependent protein kinase in intact human platelets: phosphorylation-induced actin polymerization caused by HSP27 mutants. J. Biol. Chem. 2001, 276:7108-7113.
18. Voss O.H., Batra S., Kolattukudy S.J., Gonzalez-Mejia M.E., Smith J.B., Doseff A.I. Binding of caspase-3 prodomain to heat shock protein 27 regulates monocyte apoptosis by inhibiting caspase-3 proteolytic activation. J. Biol. Chem. 2007, 282:25088-25099.
19. de Thonel A., Vandekerckhove J., Lanneau D., Selvakumar S., Courtois G., Hazoume A., Brunet M., Maurel S., Hammann A., Ribeil J.A., Zermati Y., Gabet A.S., Boyes J., Solary E., Hermine O., Garrido C. HSP27 controls GATA-1 protein level during erythroid cell differentiation. Blood 2010, 116:85-96.
20. Garrido C., Fromentin A., Bonnotte B., Favre N., Moutet M., Arrigo A.P., Mehlen P., Solary E. Heat shock protein 27 enhances the tumorigenicity of immunogenic rat colon carcinoma cell clones. Cancer Res. 1998, 58:5495-5499.
21. Brunet Simioni M., De Thonel A., Hammann A., Joly A.L., Bossis G., Fourmaux E., Bouchot A., Landry J., Piechaczyk M., Garrido C. Heat shock protein 27 is involved in SUMO-2/3 modification of heat shock factor 1 and thereby modulates the transcription factor activity. Oncogene 2009, 28:3332-3344.
22. Bruey J.M., Ducasse C., Bonniaud P., Ravagnan L., Susin S.A., Diaz-Latoud C., Gurbuxani S., Arrigo A.P., Kroemer G., Solary E., Garrido C. Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat. Cell Biol. 2000, 2:645-652.
23. Jaattela M. Escaping cell death: survival proteins in cancer. Exp. Cell Res. 1999, 248:30-43.
24. Tavaria M., Gabriele T., Kola I., Anderson R.L. A hitchhiker's guide to the human Hsp70 family. Cell Stress Chaperones 1996, 1:23-28.
25. Jaattela M., Wissing D., Kokholm K., Kallunki T., Egeblad M. Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases. EMBO J. 1998, 17:6124-6134.
26. Shi Y., Thomas J.O. The transport of proteins into the nucleus requires the 70-kilodalton heat shock protein or its cytosolic cognate. Mol. Cell. Biol. 1992, 12:2186-2192.
27. Schmitt E., Parcellier A., Gurbuxani S., Cande C., Hammann A., Morales M.C., Hunt C.R., Dix D.J., Kroemer R.T., Giordanetto F., Jaattela M., Penninger J.M., Pance A., Kroemer G., Garrido C. Chemosensitization by a non-apoptogenic heat shock protein 70-binding apoptosis-inducing factor mutant. Cancer Res. 2003, 63:8233-8240.
28. Dix D.J., Allen J.W., Collins B.W., Mori C., Nakamura N., Poorman-Allen P., Goulding E.H., Eddy E.M. Targeted gene disruption of Hsp70-2 results in failed meiosis, germ cell apoptosis, and male infertility. Proc. Natl. Acad. Sci. USA 1996, 93:3264-3268.
29. Frisan E., Vandekerckhove J., de Thonel A., Pierre-Eugene C., Sternberg A., Arlet J.B., Floquet C., Gyan E., Kosmider O., Dreyfus F., Gabet A.S., Courtois G., Vyas P., Ribeil J.A., Zermati Y., Lacombe C., Mayeux P., Solary E., Garrido C., Hermine O., Fontenay M. Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes. Blood 2012, 119:1532-1542.
30. Knowlton A.A., Grenier M., Kirchhoff S.R., Salfity M. Phosphorylation at tyrosine-524 influences nuclear accumulation of HSP72 with heat stress. Am. J. Physiol. Heart Circ. Physiol. 2000, 278:H2143-H2149.
31. Sreedhar A.S., Kalmar E., Csermely P., Shen Y.F. Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett. 2004, 562:11-15.
32. Kampinga H.H., Hageman J., Vos M.J., Kubota H., Tanguay R.M., Bruford E.A., Cheetham M.E., Chen B., Hightower L.E. Guidelines for the nomenclature of the human heat shock proteins. Cell Stress Chaperones 2009, 14:105-111.
33. Stebbins C.E., Russo A.A., Schneider C., Rosen N., Hartl F.U., Pavletich N.P. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997, 89:239-250.
34. Onuoha S.C., Coulstock E.T., Grossmann J.G., Jackson S.E. Structural studies on the co-chaperone Hop and its complexes with Hsp90. J. Mol. Biol. 2008, 379:732-744.
35. Nathan D.F., Lindquist S. Mutational analysis of Hsp90 function: interactions with a steroid receptor and a protein kinase. Mol. Cell. Biol. 1995, 15:3917-3925.
36. Shaknovich R., Shue G., Kohtz D.S. Conformational activation of a basic helix-loop-helix protein (MyoD1) by the C-terminal region of murine HSP90 (HSP84). Mol. Cell. Biol. 1992, 12:5059-5068.
37. Hartson S.D., Matts R.L. Association of Hsp90 with cellular Src-family kinases in a cell-free system correlates with altered kinase structure and function. Biochemistry 1994, 33:8912-8920.
38. Wartmann M., Davis R.J. The native structure of the activated Raf protein kinase is a membrane-bound multi-subunit complex. J. Biol. Chem. 1994, 269:6695-6701.
39. Sato S., Fujita N., Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc. Natl. Acad. Sci. USA 2000, 97:10832-10837.
40. Kovacs J.J., Murphy P.J., Gaillard S., Zhao X., Wu J.T., Nicchitta C.V., Yoshida M., Toft D.O., Pratt W.B., Yao T.P. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 2005, 18:601-607.
41. Duval M., Le Boeuf F., Huot J., Gratton J.P. Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase. Mol. Biol. Cell 2007, 18:4659-4668.
42. Didelot C., Lanneau D., Brunet M., Joly A.L., De Thonel A., Chiosis G., Garrido C. Anti-cancer therapeutic approaches based on intracellular and extracellular heat shock proteins. Curr. Med. Chem. 2007, 14:2839-2847.
43. Thomas X., Campos L., Mounier C., Cornillon J., Flandrin P., Le Q.H., Piselli S., Guyotat D. Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia. Leuk. Res. 2005, 29:1049-1058.
44. Duval A., Olaru D., Campos L., Flandrin P., Nadal N., Guyotat D. Expression and prognostic significance of heat-shock proteins in myelodysplastic syndromes. Haematologica 2006, 91:713-714.
45. Thomas X., Campos L., Le Q.H., Guyotat D. Heat shock proteins and acute leukemias. Hematology 2005, 10:225-235.
46. Michalopoulou S., Micheva I., Karakantza M., Kouraklis-Symeonidis A., Mouzaki A., Zoumbos N.C. Expression and inducibility of cytoprotective heat shock proteins in the bone marrow of patients with myelodysplastic syndrome: correlation with disease progression. Haematologica 2006, 91:1714-1716.
47. Yu W., Wang J., Jin J., Qian W., Qian J., Cheng Y., Wang L. Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor. Leuk. Res. 2011, 35:1212-1218.
48. Reikvam H., Ersvaer E., Bruserud O. Heat shock protein 90-a potential target in the treatment of human acute myelogenous leukemia. Curr. Cancer Drug Targets 2009, 9:761-776.
49. Reikvam H., Hatfield K.J., Ersvaer E., Hovland R., Skavland J., Gjertsen B.T., Petersen K., Bruserud O. Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status-consequences and potentials for pharmacological intervention. Br. J. Haematol. 2011, 156:468-480.
50. Fumo G., Akin C., Metcalfe D.D., Neckers L. 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 2004, 103:1078-1084.
51. Tsujimura A., Kiyoi H., Shiotsu Y., Ishikawa Y., Mori Y., Ishida H., Toki T., Ito E., Naoe T. Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia. Int. J. Hematol. 2010, 92:624-633.
52. Yao Q., Nishiuchi R., Kitamura T., Kersey J.H. Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway. Leukemia 2005, 19:1605-1612.
53. Mesa R.A., Loegering D., Powell H.L., Flatten K., Arlander S.J., Dai N.T., Heldebrant M.P., Vroman B.T., Smith B.D., Karp J.E., Eyck C.J., Erlichman C., Kaufmann S.H., Karnitz L.M. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood 2005, 106:318-327.
54. Lancet J.E., Gojo I., Burton M., Quinn M., Tighe S.M., Kersey K., Zhong Z., Albitar M.X., Bhalla K., Hannah A.L., Baer M.R. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia 2010, 24:699-705.
55. Kaufmann S.H., Karp J.E., Litzow M.R., Mesa R.A., Hogan W., Steensma D.P., Flatten K.S., Loegering D.A., Schneider P.A., Peterson K.L., Maurer M.J., Smith B.D., Greer J., Chen Y., Reid J.M., Ivy S.P., Ames M.M., Adjei A.A., Erlichman C., Karnitz L.M. Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. Haematologica 2011, 96:1619-1626.
56. Schmitt E., Maingret L., Puig P.E., Rerole A.L., Ghiringhelli F., Hammann A., Solary E., Kroemer G., Garrido C. Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma. Cancer Res. 2006, 66:4191-4197.
57. Clarke P.A., Hostein I., Banerji U., Stefano F.D., Maloney A., Walton M., Judson I., Workman P. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene 2000, 19:4125-4133.
58. Cortes J.E., Talpaz M., Beran M., O'Brien S.M., Rios M.B., Stass S., Kantarjian H.M. Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results. Cancer 1995, 75:464-470.
59. Deininger M.W., Goldman J.M., Melo J.V. The molecular biology of chronic myeloid leukemia. Blood 2000, 96:3343-3356.
60. Guo F., Sigua C., Bali P., George P., Fiskus W., Scuto A., Annavarapu S., Mouttaki A., Sondarva G., Wei S., Wu J., Djeu J., Bhalla K. Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. Blood 2005, 105:1246-1255.
61. Peng C., Brain J., Hu Y., Goodrich A., Kong L., Grayzel D., Pak R., Read M., Li S. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells. Blood 2007, 110:678-685.
62. Anand S., Stedham F., Beer P., Gudgin E., Ortmann C.A., Bench A., Erber W., Green A.R., Huntly B.J. Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms. Blood 2011, 118:177-181.
63. Jamieson C.H., Gotlib J., Durocher J.A., Chao M.P., Mariappan M.R., Lay M., Jones C., Zehnder J.L., Lilleberg S.L., Weissman I.L. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc. Natl. Acad. Sci. USA 2006, 103:6224-6229.
64. Marubayashi S., Koppikar P., Taldone T., Abdel-Wahab O., West N., Bhagwat N., Caldas-Lopes E., Ross K.N., Gonen M., Gozman A., Ahn J.H., Rodina A., Ouerfelli O., Yang G., Hedvat C., Bradner J.E., Chiosis G., Levine R.L. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J. Clin. Invest. 2010, 120:3578-3593.
65. Fiskus W., Verstovsek S., Manshouri T., Rao R., Balusu R., Venkannagari S., Rao N.N., Ha K., Smith J.E., Hembruff S.L., Abhyankar S., McGuirk J., Bhalla K.N. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells. Clin. Cancer Res. 2011, 17:7347-7358.
66. Chatterjee M., Jain S., Stuhmer T., Andrulis M., Ungethum U., Kuban R.J., Lorentz H., Bommert K., Topp M., Kramer D., Muller-Hermelink H.K., Einsele H., Greiner A., Bargou R.C., STAT3 MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival. Blood 2007, 109:720-728.
67. Nakashima T., Ishii T., Tagaya H., Seike T., Nakagawa H., Kanda Y., Akinaga S., Soga S., Shiotsu Y. New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells. Clin. Cancer Res. 2010, 16:2792-2802.
68. Richardson P.G., Chanan-Khan A.A., Lonial S., Krishnan A.Y., Carroll M.P., Alsina M., Albitar M., Berman D., Messina M., Anderson K.C. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. Br. J. Haematol. 2011, 153:729-740.
69. Usmani S.Z., Bona R.D., Chiosis G., Li Z. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1. J. Hematol. Oncol. 2010, 3:40.
70. Okawa Y., Hideshima T., Steed P., Vallet S., Hall S., Huang K., Rice J., Barabasz A., Foley B., Ikeda H., Raje N., Kiziltepe T., Yasui H., Enatsu S., Anderson K.C. SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 2009, 113:846-855.
71. Hideshima T., Richardson P.G., Anderson K.C. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol. Cancer Ther. 2011, 10:2034-2042.
72. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Fanourakis G., Gu X., Bailey C., Joseph M., Libermann T.A., Treon S.P., Munshi N.C., Richardson P.G., Hideshima T., Anderson K.C. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl. Acad. Sci. USA 2002, 99:14374-14379.
73. Neckers L., Workman P. Hsp90 molecular chaperone inhibitors: are we there yet?. Clin. Cancer Res. 2012, 18:64-76.
74. Davenport E.L., Zeisig A., Aronson L.I., Moore H.E., Hockley S., Gonzalez D., Smith E.M., Powers M.V., Sharp S.Y., Workman P., Morgan G.J., Davies F.E. Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma. Leukemia 2010, 24:1804-1807.
75. Garnier C., Lafitte D., Jorgensen T.J., Jensen O.N., Briand C., Peyrot V. Phosphorylation and oligomerization states of native pig brain HSP90 studied by mass spectrometry. Eur. J. Biochem. 2001, 268:2402-2407.
76. Nimmanapalli R., Fuino L., Bali P., Gasparetto M., Glozak M., Tao J., Moscinski L., Smith C., Wu J., Jove R., Atadja P., Bhalla K. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 2003, 63:5126-5135.
77. Bali P., George P., Cohen P., Tao J., Guo F., Sigua C., Vishvanath A., Scuto A., Annavarapu S., Fiskus W., Moscinski L., Atadja P., Bhalla K. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin. Cancer Res. 2004, 10:4991-4997.
78. Bali P., Pranpat M., Bradner J., Balasis M., Fiskus W., Guo F., Rocha K., Kumaraswamy S., Boyapalle S., Atadja P., Seto E., Bhalla K. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 2005, 280:26729-26734.
79. George P., Bali P., Annavarapu S., Scuto A., Fiskus W., Guo F., Sigua C., Sondarva G., Moscinski L., Atadja P., Bhalla K. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005, 105:1768-1776.
80. Nieto-Miguel T., Gajate C., Gonzalez-Camacho F., Mollinedo F. Proapoptotic role of Hsp90 by its interaction with c-Jun N-terminal kinase in lipid rafts in edelfosine-mediated antileukemic therapy. Oncogene 2008, 27:1779-1787.
81. Charette S.J., Lavoie J.N., Lambert H., Landry J. Inhibition of Daxx-mediated apoptosis by heat shock protein 27. Mol. Cell. Biol. 2000, 20:7602-7612.
82. Rane M.J., Pan Y., Singh S., Powell D.W., Wu R., Cummins T., Chen Q., McLeish K.R., Klein J.B. Heat shock protein 27 controls apoptosis by regulating Akt activation. J. Biol. Chem. 2003, 278:27828-27835.
83. Park K.J., Gaynor R.B., Kwak Y.T. Heat shock protein 27 association with the I kappa B kinase complex regulates tumor necrosis factor alpha-induced NF-kappa B activation. J. Biol. Chem. 2003, 278:35272-35278.
84. Graceffa P. Hsp27-actin interaction. Biochem. Res. Int. 2011, 2011:901572.
85. Bitar K.N. HSP27 phosphorylation and interaction with actin-myosin in smooth muscle contraction. Am. J. Physiol. Gastrointest. Liver Physiol. 2002, 282:G894-903.
86. Baylot V., Andrieu C., Katsogiannou M., Taieb D., Garcia S., Giusiano S., Acunzo J., Iovanna J., Gleave M., Garrido C., Rocchi P. OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer. Cell Death Dis. 2011, 2:e221.
87. Gibert B., Eckel B., Fasquelle L., Moulin M., Bouhallier F., Gonin V., Mellier G., Simon S., Kretz-Remy C., Arrigo A.P., Diaz-Latoud C. Knock down of heat shock protein 27 (HspB1) induces degradation of several putative client proteins. PLoS One 2012, 7:e29719.
88. Jacquier-Sarlin M.R., Jornot L., Polla B.S. Differential expression and regulation of hsp70 and hsp90 by phorbol esters and heat shock. J. Biol. Chem. 1995, 270:14094-14099.
89. Garrido C., Bruey J.M., Fromentin A., Hammann A., Arrigo A.P., Solary E. HSP27 inhibits cytochrome c-dependent activation of procaspase-9. FASEB J. 1999, 13:2061-2070.
90. Mosser D.D., Morimoto R.I. Molecular chaperones and the stress of oncogenesis. Oncogene 2004, 23:2907-2918.
91. Mosser D.D., Caron A.W., Bourget L., Meriin A.B., Sherman M.Y., Morimoto R.I., Massie B. The chaperone function of hsp70 is required for protection against stress-induced apoptosis. Mol. Cell. Biol. 2000, 20:7146-7159.
92. Kamada M., So A., Muramaki M., Rocchi P., Beraldi E., Gleave M. Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol. Cancer Ther. 2007, 6:299-308.
93. Choi D.H., Ha J.S., Lee W.H., Song J.K., Kim G.Y., Park J.H., Cha H.J., Lee B.J., Park J.W. Heat shock protein 27 is associated with irinotecan resistance in human colorectal cancer cells. FEBS Lett. 2007, 581:1649-1656.
94. Aghdassi A., Phillips P., Dudeja V., Dhaulakhandi D., Sharif R., Dawra R., Lerch M.M., Saluja A. Heat shock protein 70 increases tumorigenicity and inhibits apoptosis in pancreatic adenocarcinoma. Cancer Res. 2007, 67:616-625.
95. Compton S.A., Elmore L.W., Haydu K., Jackson-Cook C.K., Holt S.E. Induction of nitric oxide synthase-dependent telomere shortening after functional inhibition of Hsp90 in human tumor cells. Mol. Cell Biol. 2006, 26:1452-1462.
96. Gurbuxani S., Bruey J.M., Fromentin A., Larmonier N., Parcellier A., Jaattela M., Martin F., Solary E., Garrido C. Selective depletion of inducible HSP70 enhances immunogenicity of rat colon cancer cells. Oncogene 2001, 20:7478-7485.
97. Nylandsted J., Rohde M., Brand K., Bastholm L., Elling F., Jaattela M. Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2. Proc. Natl. Acad. Sci. USA 2000, 97:7871-7876.
98. Schepers H., Geugien M., van der Toorn M., Bryantsev A.L., Kampinga H.H., Eggen B.J., Vellenga E. HSP27 protects AML cells against VP-16-induced apoptosis through modulation of p38 and c-Jun. Exp. Hematol. 2005, 33:660-670.
99. Chauhan D., Li G., Hideshima T., Podar K., Mitsiades C., Mitsiades N., Catley L., Tai Y.T., Hayashi T., Shringarpure R., Burger R., Munshi N., Ohtake Y., Saxena S., Anderson K.C. Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood 2003, 102:3379-3386.
100. Georgakis G.V., Li Y., Younes A. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9. Br. J. Haematol. 2006, 135:68-71.
101. Kim Y.S., Alarcon S.V., Lee S., Lee M.J., Giaccone G., Neckers L., Trepel J.B. Update on Hsp90 inhibitors in clinical trial. Curr. Top. Med. Chem. 2009, 9:1479-1492.
102. Kawakami H., Tomita M., Okudaira T., Ishikawa C., Matsuda T., Tanaka Y., Nakazato T., Taira N., Ohshiro K., Mori N. Inhibition of heat shock protein-90 modulates multiple functions required for survival of human T-cell leukemia virus type I-infected T-cell lines and adult T-cell leukemia cells. Int. J. Cancer 2007, 120:1811-1820.
103. Boll B., Eltaib F., Reiners K.S., von Tresckow B., Tawadros S., Simhadri V.R., Burrows F.J., Lundgren K., Hansen H.P., Engert A., von Strandmann E.P. Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity. Clin. Cancer Res. 2009, 15:5108-5116.
104. Castro J.E., Prada C.E., Loria O., Kamal A., Chen L., Burrows F.J., Kipps T.J. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. Blood 2005, 106:2506-2512.
105. Jones D.T., Addison E., North J.M., Lowdell M.W., Hoffbrand A.V., Mehta A.B., Ganeshaguru K., Folarin N.I., Wickremasinghe R.G. Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells' sensitivity to cytotoxic drugs. Blood 2004, 103:1855-1861.
106. Cerchietti L.C., Lopes E.C., Yang S.N., Hatzi K., Bunting K.L., Tsikitas L.A., Mallik A., Robles A.I., Walling J., Varticovski L., Shaknovich R., Bhalla K.N., Chiosis G., Melnick A. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat. Med. 2009, 15:1369-1376.
107. De Maria R., Zeuner A., Eramo A., Domenichelli C., Bonci D., Grignani F., Srinivasula S.M., Alnemri E.S., Testa U., Peschle C. Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. Nature 1999, 401:489-493.
108. Zermati Y., Garrido C., Amsellem S., Fishelson S., Bouscary D., Valensi F., Varet B., Solary E., Hermine O. Caspase activation is required for terminal erythroid differentiation. J. Exp. Med. 2001, 193:247-254.
109. Ishizaki Y., Jacobson M.D., Raff M.C. A role for caspases in lens fiber differentiation. J. Cell Biol. 1998, 140:153-158.
110. Loones M.T., Morange M. Hsp and chaperone distribution during endochondral bone development in mouse embryo. Cell Stress Chaperones 1998, 3:237-244.
111. Mehlen P., Kretz-Remy C., Preville X., Arrigo A.P. Human hsp27, Drosophila hsp27 and human alphaB-crystallin expression-mediated increase in glutathione is essential for the protective activity of these proteins against TNFalpha-induced cell death,. EMBO J. 1996, 15:2695-2706.
112. Trinklein N.D., Chen W.C., Kingston R.E., Myers R.M. Transcriptional regulation and binding of heat shock factor 1 and heat shock factor 2 to 32 human heat shock genes during thermal stress and differentiation. Cell Stress Chaperones 2004, 9:21-28.
113. Mehlen P., Mehlen A., Godet J., Arrigo A.P. hsp27 as a switch between differentiation and apoptosis in murine embryonic stem cells. J. Biol. Chem. 1997, 272:31657-31665.
114. Shakoori A.R., Oberdorf A.M., Owen T.A., Weber L.A., Hickey E., Stein J.L., Lian J.B., Stein G.S. Expression of heat shock genes during differentiation of mammalian osteoblasts and promyelocytic leukemia cells. J. Cell. Biochem. 1992, 48:277-287.
115. Spector N.L., Ryan C., Samson W., Levine H., Nadler L.M., Arrigo A.P. Heat shock protein is a unique marker of growth arrest during macrophage differentiation of HL-60 cells. J. Cell. Physiol. 1993, 156:619-625.
116. Spector N.L., Mehlen P., Ryan C., Hardy L., Samson W., Levine H., Nadler L.M., Fabre N., Arrigo A.P. Regulation of the 28kDa heat shock protein by retinoic acid during differentiation of human leukemic HL-60 cells. FEBS Lett. 1994, 337:184-188.
117. Chaufour S., Mehlen P., Arrigo A.P. Transient accumulation, phosphorylation and changes in the oligomerization of Hsp27 during retinoic acid-induced differentiation of HL-60 cells: possible role in the control of cellular growth and differentiation. Cell Stress Chaperones 1996, 1:225-235.
118. Ishiwatari S., Suzuki T., Hitomi T., Yoshino T., Matsukuma S., Tsuji T. Effects of methyl paraben on skin keratinocytes. J. Appl. Toxicol. 2007, 27:1-9.
119. Ito H., Kamei K., Iwamoto I., Inaguma Y., Kato K. Regulation of the levels of small heat-shock proteins during differentiation of C2C12 cells. Exp. Cell Res. 2001, 266:213-221.
120. Arrigo A.P. In search of the molecular mechanism by which small stress proteins counteract apoptosis during cellular differentiation. J. Cell. Biochem. 2005, 94:241-246.
121. Liu Q.L., Kishi H., Ohtsuka K., Muraguchi A. Heat shock protein 70 binds caspase-activated DNase and enhances its activity in TCR-stimulated T cells. Blood 2003, 102:1788-1796.
122. Lin K., Rockliffe N., Johnson G.G., Sherrington P.D., Pettitt A.R. Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells. Oncogene 2008, 27:2445-2455.
123. Wei M.C., Zong W.X., Cheng E.H., Lindsten T., Panoutsakopoulou V., Ross A.J., Roth K.A., MacGregor G.R., Thompson C.B., Korsmeyer S.J., Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001, 292:727-730.
124. Tsukahara F., Maru Y. Identification of novel nuclear export and nuclear localization-related signals in human heat shock cognate protein 70. J. Biol. Chem. 2004, 279:8867-8872.
125. Grebenova D., Kuzelova K., Pluskalova M., Peslova G., Halada P., Hrkal Z. The proteomic study of sodium butyrate antiproliferative/cytodifferentiation effects on K562 cells. Blood Cells Mol. Dis. 2006, 37:210-217.
126. Yamada T., Hashiguchi A., Fukushima S., Kakita Y., Umezawa A., Maruyama T., Hata J. Function of 90-kDa heat shock protein in cellular differentiation of human embryonal carcinoma cells. In Vitro Cell Dev. Biol. Anim. 2000, 36:139-146.
127. Ellis R.J. Molecular chaperones: pathways and networks. Curr. Biol. 1999, 9:R137-139.
128. Zhang M.H., Lee J.S., Kim H.J., Jin D.I., Kim J.I., Lee K.J., Seo J.S. HSP90 protects apoptotic cleavage of vimentin in geldanamycin-induced apoptosis. Mol. Cell. Biochem. 2006, 281:111-121.
129. Chen C.F., Chen Y., Dai K., Chen P.L., Riley D.J., Lee W.H. A new member of the hsp90 family of molecular chaperones interacts with the retinoblastoma protein during mitosis and after heat shock. Mol. Cell. Biol. 1996, 16:4691-4699.
130. Xanthoudakis S., Roy S., Rasper D., Hennessey T., Aubin Y., Cassady R., Tawa P., Ruel R., Rosen A., Nicholson D.W. Hsp60 accelerates the maturation of pro-caspase-3 by upstream activator proteases during apoptosis. EMBO J. 1999, 18:2049-2056.
131. Mehlen P., Schulze-Osthoff K., Arrigo A.P. Small stress proteins as novel regulators of apoptosis. Heat shock protein 27 blocks Fas/APO-1- and staurosporine-induced cell death. J. Biol. Chem. 1996, 271:16510-16514.
132. Nimmanapalli R., O'Bryan E., Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res. 2001, 61:1799-1804.
133. Yu W., Rao Q., Wang M., Tian Z., Lin D., Liu X., Wang J. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level. Leuk. Res. 2006, 30:575-582.
134. Panner A., Murray J.C., Berger M.S., Pieper R.O. Heat shock protein 90alpha recruits FLIPS to the death-inducing signaling complex and contributes to TRAIL resistance in human glioma. Cancer Res. 2007, 67:9482-9489.
135. Lewis J., Devin A., Miller A., Lin Y., Rodriguez Y., Neckers L., Liu Z.G. Disruption of hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-kappaB activation. J. Biol. Chem. 2000, 275:10519-10526.
136. Heaney M.L., Golde D.W. Myelodysplasia. N. Engl. J. Med. 1999, 340:1649-1660.
137. Rosenfeld C., List A. A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies. Leukemia 2000, 14:2-8.
138. Heyman M.R. Recent advances in biology and treatment of myelodysplasia. Curr. Opin. Oncol. 1991, 3:44-53.
139. Albitar M., Manshouri T., Shen Y., Liu D., Beran M., Kantarjian H.M., Rogers A., Jilani I., Lin C.W., Pierce S., Freireich E.J., Estey E.H. Myelodysplastic syndrome is not merely "preleukemia". Blood 2002, 100:791-798.
140. Claessens Y.E., Fontenay-Roupie M. Physiopathology of myelodysplastic syndromes. Pathol. Biol. (Paris) 2002, 50:261-267.
141. Parker J.E., Mufti G.J. Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes. Br. J. Haematol. 1998, 101:220-230.
142. Ribeil J.A., Zermati Y., Vandekerckhove J., Cathelin S., Kersual J., Dussiot M., Coulon S., Moura I.C., Zeuner A., Kirkegaard-Sorensen T., Varet B., Solary E., Garrido C., Hermine O. Hsp70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1. Nature 2007, 445:102-105.
143. Mariz J.M., Esteves G.V. Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide. Curr. Opin. Oncol. 2012, 24(Suppl. 2):S3-11.
144. Yao Q., Nishiuchi R., Li Q., Kumar A.R., Hudson W.A., Kersey J.H. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. Clin. Cancer Res. 2003, 9:4483-4493.
145. Kamal A., Thao L., Sensintaffar J., Zhang L., Boehm M.F., Fritz L.C., Burrows F.J. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425:407-410.
146. Vilenchik M., Solit D., Basso A., Huezo H., Lucas B., He H., Rosen N., Spampinato C., Modrich P., Chiosis G. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem. Biol. 2004, 11:787-797.
147. Workman P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett. 2004, 206:149-157.
148. Ray S., Lu Y., Kaufmann S.H., Gustafson W.C., Karp J.E., Boldogh I., Fields A.P., Brasier A.R. Genomic mechanisms of p210BCR-ABL signaling: induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis. J. Biol. Chem. 2004, 279:35604-35615.
149. Zhao Z.G., Shen W.L. Heat shock protein 70 antisense oligonucleotide inhibits cell growth and induces apoptosis in human gastric cancer cell line SGC-7901. World J. Gastroenterol. 2005, 11:73-78.
150. Jaattela M. Heat shock proteins as cellular lifeguards. Ann. Med. 1999, 31:261-271.
151. Gurbuxani S., Schmitt E., Cande C., Parcellier A., Hammann A., Daugas E., Kouranti I., Spahr C., Pance A., Kroemer G., Garrido C. Heat shock protein 70 binding inhibits the nuclear import of apoptosis-inducing factor. Oncogene 2003, 22:6669-6678.
152. Leu J.I., Pimkina J., Pandey P., Murphy M.E., George D.L. HSP70 inhibition by the small-molecule 2-phenylethynesulfonamide impairs protein clearance pathways in tumor cells. Mol. Cancer Res. 2011, 9:936-947.
153. Chalmin F., Ladoire S., Mignot G., Vincent J., Bruchard M., Remy-Martin J.P., Boireau W., Rouleau A., Simon B., Lanneau D., De Thonel A., Multhoff G., Hamman A., Martin F., Chauffert B., Solary E., Zitvogel L., Garrido C., Ryffel B., Borg C., Apetoh L., Rebe C., Ghiringhelli F. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Invest. 2010, 120:457-471.
154. Rerole A.L., Gobbo J., De Thonel A., Schmitt E., Pais de Barros J.P., Hammann A., Lanneau D., Fourmaux E., Deminov O., Micheau O., Lagrost L., Colas P., Kroemer G., Garrido C. Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy. Cancer Res. 2011, 71:484-495.
155. Stangl S., Gehrmann M., Riegger J., Kuhs K., Riederer I., Sievert W., Hube K., Mocikat R., Dressel R., Kremmer E., Pockley A.G., Friedrich L., Vigh L., Skerra A., Multhoff G. Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody. Proc. Natl. Acad. Sci. USA 2011, 108:733-738.
156. Dorard C., de Thonel A., Collura A., Marisa L., Svrcek M., Lagrange A., Jego G., Wanherdrick K., Joly A.L., Buhard O., Gobbo J., Penard-Lacronique V., Zouali H., Tubacher E., Kirzin S., Selves J., Milano G., Etienne-Grimaldi M.C., Bengrine-Lefevre L., Louvet C., Tournigand C., Lefevre J.H., Parc Y., Tiret E., Flejou J.F., Gaub M.P., Garrido C., Duval A. Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis. Nat. Med. 2011, 17:1283-1289.
157. Solary E., Droin N., Bettaieb A., Corcos L., Dimanche-Boitrel M.T., Garrido C. Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies. Leukemia 2000, 14:1833-1849.
158. Heinrich J.C., Tuukkanen A., Schroeder M., Fahrig T., Fahrig R. RP101 (brivudine) binds to heat shock protein HSP27 (HSPB1) and enhances survival in animals and pancreatic cancer patients. J. Cancer Res. Clin. Oncol. 2011, 137:1349-1361.
159. Gibert B., Hadchity E., Czekalla A., Aloy M.T., Colas P., Rodriguez-Lafrasse C., Arrigo A.P., Diaz-Latoud C. Inhibition of heat shock protein 27 (HspB1) tumorigenic functions by peptide aptamers. Oncogene 2011, 30:3672-3681.
160. Westerheide S.D., Kawahara T.L., Orton K., Morimoto R.I. Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death. J. Biol. Chem. 2006, 281:9616-9622.
161. Sangster T.A., Bahrami A., Wilczek A., Watanabe E., Schellenberg K., McLellan C., Kelley A., Kong S.W., Queitsch C., Lindquist S. Phenotypic diversity and altered environmental plasticity in Arabidopsis thaliana with reduced Hsp90 levels. PLoS One 2007, 2:e648.
162. Wyttenbach A., Sauvageot O., Carmichael J., Diaz-Latoud C., Arrigo A.P., Rubinsztein D.C. Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum. Mol. Genet. 2002, 11:1137-1151.
163. Arrigo A.P., Simon S., Gibert B., Kretz-Remy C., Nivon M., Czekalla A., Guillet D., Moulin M., Diaz-Latoud C., Vicart P. Hsp27 (HspB1) and alphaB-crystallin (HspB5) as therapeutic targets. FEBS Lett. 2007, 581:3665-3674.
164. Kummar S., Gutierrez M.E., Gardner E.R., Chen X., Figg W.D., Zajac-Kaye M., Chen M., Steinberg S.M., Muir C.A., Yancey M.A., Horneffer Y.R., Juwara L., Melillo G., Ivy S.P., Merino M., Neckers L., Steeg P.S., Conley B.A., Giaccone G., Doroshow J.H., Murgo A.J. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur. J. Cancer 2010, 46:340-347.
165. K. Jhaveri, T. Taldone, S. Modi, G. Chiosis, Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers, Biochim. Biophys. Acta (2011).
166. Richardson P.G., Mitsiades C.S., Laubach J.P., Lonial S., Chanan-Khan A.A., Anderson K.C. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br. J. Haematol. 2011, 152:367-379.
167. Peng C., Li D., Li S. Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors. Cell Cycle 2007, 6:2227-2231.
168. Sharp S., Workman P. Inhibitors of the HSP90 molecular chaperone: current status. Adv. Cancer Res. 2006, 95:323-348.
169. Taldone T., Gozman A., Maharaj R., Chiosis G. Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr. Opin. Pharmacol. 2008, 8:370-374.
170. Porter J.R., Fritz C.C., Depew K.M. Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr. Opin. Chem. Biol. 2010, 14:412-420.